YM-358 potassium hydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526924

CAS#: 161800-08-4 (potassium hydrate)

Description: YM-358 potassium hydrate is a angiotensin type 1 receptor antagonist potentially for the treatment of hypertension and chronic heart. YM358 is both orally active and long-lasting. YM358 has higher efficacy than enalapril for the treatment of hypertension.

Chemical Structure

YM-358 potassium hydrate
CAS# 161800-08-4 (potassium hydrate)

Theoretical Analysis

MedKoo Cat#: 526924
Name: YM-358 potassium hydrate
CAS#: 161800-08-4 (potassium hydrate)
Chemical Formula: C22H23KN8O
Exact Mass:
Molecular Weight: 454.5793
Elemental Analysis: C, 58.13; H, 5.10; K, 8.60; N, 24.65; O, 3.52

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: YM-358 potassium hydrate; YM-358; YM 358; YM358.

IUPAC/Chemical Name: potassium 5-(4'-((2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-2-ide hydrate


InChi Code: InChI=1S/C22H21N8.K.H2O/c1-3-16-14-29(30-22(16)23-20(4-2)26-30)13-15-9-11-17(12-10-15)18-7-5-6-8-19(18)21-24-27-28-25-21;;/h5-12,14H,3-4,13H2,1-2H3;;1H2/q-1;+1;

SMILES Code: CCC1=CN(CC2=CC=C(C3=CC=CC=C3C4=NN([K])N=N4)C=C2)N5N=C(CC)N=C51.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 454.5793 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Oka-Akagi T, Fujimori A, Shibasaki M, Matsuda-Satoh Y, Inagaki O, Yanagisawa I. Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats. Biol Pharm Bull. 2002 Jul;25(7):857-60. PubMed PMID: 12132657.

2: Tokioka-Akagi T, Fujimori A, Shibasaki M, Inagaki O, Yanagisawa I. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload. Jpn J Pharmacol. 2001 May;86(1):79-85. PubMed PMID: 11430476.

3: Tokioka T, Shibasaki M, Fujimori A, Matsuda-Satoh Y, Uchida W, Inagaki O, Yanagisawa I. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81. PubMed PMID: 10706380.

4: Sekine T, Kusano H, Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Developmental conversion of inotropism by endothelin I and angiotensin II from positive to negative in mice. Eur J Pharmacol. 1999 Jun 25;374(3):411-5. PubMed PMID: 10422785.

5: Okazaki T, Suga A, Watanabe T, Kikuchi K, Kurihara H, Shibasaki M, Fujimori A, Inagaki O, Yanagisawa U. Studies on nonpeptide angiotensin II receptor antagonists. I. Synthesis and biological evaluation of pyrazolo[1,5-b][1,2,4]triazole derivatives with alkyl substituents. Chem Pharm Bull (Tokyo). 1998 Jan;46(1):69-78. PubMed PMID: 9468638.

6: Shibasaki M, Fujimori A, Kusayama T, Tokioka T, Satoh Y, Okazaki T, Uchida W, Inagaki O, Yanagisawa I. Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs. Eur J Pharmacol. 1997 Sep 24;335(2-3):175-84. PubMed PMID: 9369371.

7: Shibasaki M, Fujimori A, Takanashi M, Kusayama T, Tokioka T, Satoh Y, Okazaki T, Uchida W, Inagaki O, Yanagisawa I. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist. Eur J Pharmacol. 1997 Sep 24;335(2-3):167-73. PubMed PMID: 9369370.

8: Yamaguchi N, Fujimoto K, Fujii T, Suzuki T, Kawashima K. Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol. 1997 Jan;73(1):83-91. PubMed PMID: 9032137.

Additional Information

Related CAS#
151406-07-4 (YM-358 free)
161800-08-4 (YM-358 potassium hydrate)